The information provided on this page is for reference only. Please refer to the latest information published by the partner company.
Our mission is to develop and commercialize an artificial intelligence-assisted retinal nerve fiber layer optical texture analysis (AIROTA) system, a cloud-based algorithm that automates clinical workflow for diagnostic evaluation and screening of glaucoma – the leading cause of irreversible blindness – and non-glaucomatous optic neuropathies. AIROTA is developed based on our patented technology ROTA, retinal nerve fiber layer (RNFL) optical texture analysis, a validated novel image processing system using optical coherence tomography (OCT) data to discern axonal fiber bundles for detection of RNFL abnormalities. The implementation of AIROTA will (1) transform the diagnostic paradigm in clinical management of glaucoma and non-glaucomatous optic neuropathies; (2) empower clinicians and eye care professional to identify patients at risk for visual impairment for treatment; and (3) facilitate rational allocation of healthcare resources.
We invented and validated a new technique, ROTA (Retinal nerve fiber layer Optical Texture Analysis) (US Application No.62/571,559), to augment the diagnostic performance to detect glaucoma and non-glaucomatous optic neuropathies. Our product is a global cloud platform of AI-assisted ROTA analysis (AIROTA), which integrates (1) ROTA, (2) cloud computing, and (3) deep learning into major clinical optical coherence tomography systems worldwide to automate clinical workflow for diagnostic evaluation and screening of glaucoma and non-glaucomatous optic neuropathies. Our business model represents a key strategy for prevention of blindness and visual impairment in Hong Kong and beyond, which is aligned with the Government initiative to promote healthcare.